OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 20:40:53 21/06/2024 BST | ||
| 14.26 EUR | -0.63% |
|
| Current month | +10.89% | ||
| 1 month | +22.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 14.26 | -0.63% |
| 20/06/24 | 14.35 | +2.87% |
| 19/06/24 | 13.95 | -0.85% |
| 18/06/24 | 14.07 | -4.29% |
| 17/06/24 | 14.7 | -4.73% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 08:40 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC3NX5 |
| ISIN | DE000HC3NX58 |
| Date issued | 30/01/2023 |
| Strike | 318 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.59 € |
|---|---|
| Lowest since issue | 0.52 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
